Table 3.

Clinical Characteristics of the FGF-23 Trajectory Groups at the Onset of the Survival Time (time 0, fifth annual study visit)

	FGF-23 Trajectory Group
	Stable (n = 643)	Slowly Increasing (n = 409)	Rapidly Increasing (n = 111)
Age, y	61.7 ± 10.8	61.6 ± 11.1	59.6 ± 10.9
Female sex	39.2%	51.8%	55.0%
Black	41.5%	43.5%	51.4%
Hispanic	8.2%	14.7%	17.1%
Current smoking	6.9%	14.2%	10.6%
Body mass index, kg/m2	31.8 ± 7.6	33.3 ± 8.7	32.7 ± 9.5
Systolic blood pressure, mm Hg	127.0 ± 21.8	132.2 ± 22.9	134.2 ± 21.1
Diabetes	48.5%	63.9%	61.1%
Heart failure	9.7%	17.7%	27.7%
Stroke	9.4%	14.8%	17.7%
Peripheral vascular disease	7.2%	14.4%	17.3%
Coronary artery disease	24.3%	29.9%	36.0%
No. of hypertension medications	2.4 ± 1.3	2.8 ± 1.2	3.1 ± 1.0
ACEi/ARB use	66.7%	63.3%	53.5%
IL-6, pg/mLa	1.5 [0.9–2.6]	2.1 [1.3–3.4]	2.1 [1.4–3.7]
CRP, mg/La	2.2 [1.0–6.0]	2.8 [1.2–6.9]	3.4 [0.8–7.3]
UPCR, g/g	0.11 [0.06–0.39]	0.59 [0.15–1.75]	1.11 [0.42–2.56]
Hemoglobin, g/dL	12.8 ± 1.7	11.8 ± 1.7	11.2 ± 1.7
Serum albumin, g/dL	4.0 ± 0.4	3.8 ± 0.4	3.7 ± 0.4
Calcium, mg/dL	9.3 ± 0.5	9.2 ± 0.6	9.2 ± 0.6
Phosphate, mg/dL	4.0 ± 0.8	4.3 ± 0.9	4.7 ± 0.9
PTH, pg/mL	80.6 [43.3–155.9]	133.0 [75.2–220.9]	191.8 [107.0–281.8]
Baseline FGF-23, RU/mL	103.0 [78.4–137.2]	197.7 [145.4–273.1]	334.8 [247.5–502.9]
Final FGF-23, RU/mL	123.7 [83.2–202.5]	402.2 [241.0–761.7]	1,698.0 [995.0–3,085.1]
Baseline eGFR, mL/min/1.73 m2	50.4 ± 13.5	39.7 ± 12.0	34.9 ± 11.8
Final eGFR, mL/min/1.73 m2	45.6 ± 17.1	31.4 ± 15.5	21.7 ± 12.3

Note: Results are reported as proportion. mean ± standard deviation, or median [interquartile range].

Abbreviations: ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; FGF-23, fibroblast growth factor 2; IL-6, interleukin 6; PTH, parathyroid hormone; UPCR, urine protein-creatinine ratio.

^aCRP and IL-6 are from baseline.